Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRP | O00591 | 2/20 | 0.42 |
| ▸ | GABRD | O14764 | 2/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 2/20 | 0.42 |
| ▸ | GABRB1 | P18505 | 2/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 2/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 2/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 2/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.42 |
| ▸ | GABRA4 | P48169 | 2/20 | 0.42 |
| ▸ | GABRE | P78334 | 2/20 | 0.42 |
| ▸ | GABRA6 | Q16445 | 2/20 | 0.42 |
| ▸ | GABRG1 | Q8N1C3 | 2/20 | 0.42 |
| ▸ | GABRG3 | Q99928 | 2/20 | 0.42 |
| ▸ | GABRQ | Q9UN88 | 2/20 | 0.42 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 5/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31253328 | 1.00 | GABRP (0.42) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL27418781 | 0.94 | GABRP (0.40) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL17648999 | 0.81 | NAPRT (0.47) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL20327780 | 0.81 | SMN1; SMN2 (0.39) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL29378242 | 0.80 | SMN1; SMN2 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL56617 | 0.80 | SMN1; SMN2 (0.50) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL7897938 | 0.78 | ALDH1A1 (0.45) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| SCHEMBL31253327 | 0.78 | — | — | |
| Water SCHEMBL28081708 | 0.78 | SMN1; SMN2 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 | |
| Hydrochloric Acid SCHEMBL2523036 | 0.78 | SMN1; SMN2 (0.48) | GABRPGABRDGABRA1GABRB1GABRG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-10014591-A | — | — | None | — | — | JP | disclosed |
| EP-2958562-B1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-119504571-A | Right-embedded alcohol or fenchyl alcohol ester derivatives of 2-hydroxy nicotinic acid and pharmaceutical application thereof | 苏州缘聚医药科技有限公司 | 2025-02-25 | — | — | CN | disclosed |
| EP-4466258-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | HOFFMANN-LA ROCHE INC. (US) | 2024-11-21 | — | — | US | disclosed |
| CN-118591534-A | Novel benzimidazole pyridine derivatives | 豪夫迈·罗氏有限公司 | 2024-09-03 | — | — | CN | disclosed |
| CN-118206481-A | Right-embedded alcohol or fenchyl alcohol ester derivatives of 2-hydroxy nicotinic acid and pharmaceutical application thereof | 苏州南医大创新中心 | 2024-06-18 | — | — | CN | disclosed |
| WO-2024069448-A1 | SUBSTITUTED 1-ARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS, SUBSTITUTED 1-HETEROARYLAMINOCARBONYL-1'-HETEROARYL COMPOUNDS AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-04-04 | — | — | WO | disclosed |
| WO-2023139085-A1 | NEW BENZIMIDAZOLE PYRIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2023-07-27 | — | — | WO | disclosed |
| WO-2022125736-A1 | A TAUTOMERIC LIGAND ENABLES BIOMIMETIC C-H HYDROXYLATION WITH MOLECULAR OXYGEN | THE SCRIPPS RESEARCH INSTITUTE (US) | 2022-06-16 | — | — | WO | disclosed |
| US-20160002255-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-01-07 | — | — | US | disclosed |
| US-20160002255-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME LLC | 2016-01-07 | — | — | US | disclosed |
| EP-2958562-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | Merck Sharp & Dohme Corp. (US) | 2015-12-30 | — | — | EP | disclosed |
| WO-2014130608-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2014130608-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | MERCK SHARP & DOHME CORP. (US) | 2014-08-28 | — | — | WO | disclosed |
| WO-2002029021-A2 | BIOTECHNOLOGICAL METHOD FOR PREPARING CARBOXYLIC ACIDS WITH A HYDROXY-NITROGEN HETEROCYCLE | LONZA AG (CH) | 2002-04-11 | — | — | WO | disclosed |
| JP-H1014591-A | PRODUCTION OF 2-HYDROXY-NITROGEN-CONTAINING 6-MEMBERED RING COMPOUND | MITSUBISHI CHEM CORP | 1998-01-20 | — | — | JP | disclosed |
| US-5364940-A | For treatment of sewage sludge with cultures | LONZA LTD. (CH) | 1994-11-15 | — | — | US | disclosed |
| US-5306630-A | Microbiological process for hydroxylation of nitrogen-heterocyclic-carboxylic acids | LONZA LTD. (CH) | 1994-04-26 | — | — | US | disclosed |
| EP-0225172-A1 | Process for the preparation of 5-chloro and 5-bromo-2-hydroxynicotinicacids | A.H. ROBINS COMPANY, INCORPORATED (US) | 1987-06-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383875-A1 | Benzimidazole Pyridine Derivatives | H1-3, H1-2, H1-4 | GABRP 956/4885GABRD 1948/4885GABRA1 329/4885 |
| US-20160002255-A1 | ANTIDIABETIC BICYCLIC COMPOUNDS | GPR119, GPR65, GLP1R | GABRP 409/4885GABRD 429/4885GABRA1 364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.